Search
for
Did you mean Phosphodiesterase Inhibitors?
Sort by
Research 30 of 551
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
- PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
- Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
- The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms
- The effects of phosphodiesterase 3 (PDE3) inhibitor on hair follicle cell viability and hair growth
- Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?
- 467 Novel selective phosphodiesterase inhibitors promote the adipogenic function of dermal fibroblasts: Implication to treat hair loss
- Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
- 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- FDA approves label addition for PDE-5 inhibitor
- Alopecia areata
- Lack of efficacy of apremilast in 9 patients with severe alopecia areata
- Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
- Apremilast is efficacious in refractory alopecia areata
- Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
- Alopecia areata: from pathophysiology to therapeutic innovation
- 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
- Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
- 22-Year-Old Male with Several Discrete Patches of Hair Loss
- The pharmacological treatment of alopecia areata
- Adverse effects of common medications on male fertility
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia